Chronic Recurrent Cellulitis
Investigational use for chronic recurrent (non-acute) cellulitis with underlying lymphedema or venous insufficiency.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for chronic cellulitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic recurrent cellulitis is investigational and considered inappropriate.
- What evidence exists?
- Tier C (investigational). No controlled trial was identified; the only benefit report found is a brief Russian conference summary of 23 people with erysipelas of the lower leg, whereas published case reports describe cellulitis caused by leech therapy or leech bites. Evidence-based therapy for chronic/recurrent cellulitis: identification and treatment of predisposing factors (lymphedema, tinea pedis, venous insufficiency, obesity), antibiotic prophylaxis (penicillin V 250 mg twice daily) per PATCH trial evidence, compression for lymphedema, treatment of acute episodes with appropriate antibiotics (cephalexin, dicloxacillin, cefadroxil; clindamycin or vancomycin if MRSA suspected). Leech therapy in active or chronic cellulitis is contraindicated as it introduces Aeromonas and disrupts the skin barrier.
- Main risks
- Severe risk of worsening cellulitis or new bacterial superinfection from leech bites
- Aeromonas hydrophila infection layered on top of existing bacterial infection
- Bleeding from bite sites for 6 to 24 hours after detachment
- Sepsis or bacteremia in patients with skin barrier disruption
- Allergic reaction to leech saliva (uncommon)
- Worsening lymphedema or venous insufficiency from procedural trauma
- Delay of evidence-based antibiotic prophylaxis (penicillin V)
- Risk of necrotizing fasciitis if rapid spread occurs
- Who should not consider this
- Patients with active cellulitis or any signs of skin infection (absolute contraindication)
- Patients with severe lymphedema or venous stasis ulcers
- Patients with diabetes and peripheral arterial disease
- Immunocompromised patients (HIV, transplant, chemotherapy)
- Patients on anticoagulants, with hemophilia, or with anemia
- Patients who have not been offered antibiotic prophylaxis (penicillin V per PATCH trial)
- What to ask your clinician
- Have I been offered antibiotic prophylaxis (penicillin V 250 mg twice daily per PATCH trial)?
- Have predisposing factors been addressed (tinea pedis, lymphedema, venous insufficiency, obesity)?
- Am I a candidate for compression therapy for lymphedema?
- What evidence specifically supports leech therapy for chronic cellulitis?
- What is the realistic risk of triggering worse infection with leech bites?
- Is there an infection-control plan for the bite sites?
- Should I see infectious disease or vascular medicine instead?
- When to seek urgent care
- Rapidly spreading redness, severe pain disproportionate to appearance (suspect necrotizing fasciitis — emergency)
- Crepitus, dusky skin, or bullae (necrotizing soft tissue infection)
- Fever, chills, hypotension, or confusion (possible sepsis)
- Spreading redness, warmth, pus, or red streaks beyond initial cellulitis area
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for chronic cellulitis.
- One uncontrolled conference summary does NOT establish safety or efficacy in patients with skin infections.
- It does NOT substitute for antibiotic prophylaxis (penicillin V per PATCH trial evidence).
- It does NOT replace addressing predisposing factors (tinea pedis, lymphedema, venous insufficiency).
- It does NOT mean leech application is safe on infected or post-infectious skin — Aeromonas plus existing flora is a recipe for sepsis.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L03.90, I89.0, L03.119
- Safety tier
- High
Evidence Summary
No controlled clinical trial or published case series of leech therapy for the prevention of recurrent cellulitis in chronic lymphedema or venous insufficiency was identified in PubMed, Europe PMC, ClinicalTrials.gov, or Russian- and German-language searches. The only benefit report found is a Russian conference summary (Bondarevsky 1998, as described in the Baskova and Isakhanyan 2004 monograph) of 23 patients with lower-leg erysipelas given local leech therapy within a complex treatment, with no recurrences reported over two years; it was uncontrolled, and the monograph gives no details on the patients' underlying conditions or on timing relative to the acute episode. In contrast, published case reports describe cellulitis or other infection after leech therapy or leech bites (for example Giltner et al. 2013, PMID 23363826; Kilic & Ak 2019, PMID 31392237; Najjari et al. 2022, PMID 36317193). Any proposed lymphatic or venous decongestive mechanism is speculative and unproven for this indication. Critical safety note: leech therapy is contraindicated during the acute phase of cellulitis because of the risk of Aeromonas (including Aeromonas hydrophila) co-infection from the leech gut flora. Established preventive measures — antibiotic prophylaxis (for example penicillin V or erythromycin) per current infectious-disease guidance, compression, and meticulous skin care — remain the standard. ASH position: any use of leech therapy in this setting is investigational, has no reliable clinical support, and carries a documented infection risk.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Chronic recurrent cellulitis as a separate condition is not described in the books; Baskova and Isakhanyan write about erysipelas of the skin: they name it in the list of indications for hirudotherapy and retell an observation of 23 patients with erysipelas of the lower leg (Bondarevsky, 1998), in whom, in this retelling, pain decreased, the infiltration in the lesion resolved, and no relapses of the disease were noted during two years of follow-up[B1].
- Whether these were acute cases or recurrent ones, what other treatment the patients received (for example, antibiotics), whether they were compared with anyone, and what was counted as a relapse is not clear from the text; in another place in the book an author with the same name and year is mentioned as having used hirudotherapy as part of a complex of treatment measures in erysipelas, and what was in this complex is not stated[B1].
- Among the local reactions to hirudotherapy, Baskova and Isakhanyan name pain, bleeding, reddening of the skin, tissue swelling, enlargement of lymph nodes, itching of the skin, pyoderma, an ulcerative-necrotic process and erysipelas of the skin; if, for example, infection of wounds or erysipelas of the skin arises during leech treatment, they recognize this as a complication provoked by the treatment itself; in complications, in their words, antibiotics, sedatives and antihistamines are indicated, and they advise refraining from leeches at high body temperature[B1].
- Michalsen, in the chapter on safety, reports that according to a hospital survey, among the more severe local inflammations there were three isolated cases: one patient developed erysipelas, two developed moderate lymphangitis; all resolved quickly with antibiotic treatment (cephalosporins and/or gyrase inhibitors); how many patients this survey comprised is not stated at this point[B3].
- Flecken and Michalsen, in the chapter on contraindications, write that, by experience, in the acute stage of an infectious disease hirudotherapy may cause a feeling of weakness and impair wound healing, and that according to the broader concepts of naturopathic medicine and humoral pathology, treatment that extracts blood in infections is considered counterproductive and is not recommended; Michalsen adds that in unclear cases of progressive, painful reddening of the skin, especially with increased temperature, the physician performing hirudotherapy must know to give antibiotics immediately[B3].
- Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
- Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active acute cellulitis
- Active deep tissue infection
Related Conditions
Primary or Secondary Lymphedema
Investigational adjunctive use; no clinical study of leech therapy for lymphedema was identified.
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label adjunct to compression; the journal evidence is one small open-label randomized trial in varicose veins (n=50) and a 20-patient uncontrolled series; the books describe further reports (see “What the books describe” below).
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.